Stellate Ganglion Block in Herpes Zoster
Key facts
- Who runs it
- Tanta University
- Where
- Egypt3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 208 people enrolled
- Started
- 1 May 2020
- Ended
- 2 Feb 2025
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Stellate ganglion block
- Sham Stellate ganglion block
- Record updated
- 13 February 2025
Who can take part
- Age
- 60 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patients who is presented to the pain clinic, diagnosed with acute herpes zoster of the face and/ or neck with onset of vesicular eruption less than seven days
Who cannot take part
- Known history of allergy to local anesthetics
- Local infection at the site of the block
- Platelet count less than 75,000/ cc
- Patient refusal or un-cooperation
- Neurological deficit in the upper limb
- Glaucoma
- Bradycardia
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Patient who will be presented to Tanta University Hospitals complaining of acute herpes zoster with onset of vesicular eruption less than 7 days will be included in this clinical study.
Read full original descriptionShow less
Patients will be excluded if they refused participation, had allergy to local anesthetics, coagulopathy, local infection, glaucoma, or neurological deficit.
All the patients will receive acyclovir (antiviral therapy) and pregablin (analgesic) and the patients will be classified into two groups:- Group I (control group): Patients will receive sham block weekly for three times Group III (SGB group): Patients will receive stellate ganglion block weekly for three times
The time of first block after the onset of vesicular eruption, the incidence of PHN, NPRS at visit, duration of acute HZ , duration of PHN (if occurred), and the incidence of complication will be measured.
The 2 groups in the trial
- Control group(Group I)Sham treatment, for comparison
Patients will receive sham stellate ganglion block weekly for three times
Treatment: Sham Stellate ganglion block
- Stellate Ganglion block group (Group II)Treatment being tested
Patients will receive stellate ganglion block weekly for three times with injection of 6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg
Treatment: Stellate ganglion block
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Utility of Early Serial Stellate Ganglion Block in Acute Herpes Zoster of Face and Neck
- Record updated
- 13 February 2025